A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects

The optimal schedule for recombinant interleukin-2 (rIL-2) administration is unclear. Because the clinical and immunological effects of prolonged continuous exposure to rIL-2 are unknown, we have conducted a phase I study to assess the toxicity and feasibility of continuous low dose infusion of rIL-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 1992-05, Vol.65 (5), p.744-750
Hauptverfasser:	Vlasveld, L T, Rankin, E M, Hekman, A, Rodenhuis, S, Beijnen, J H, Hilton, A M, Dubbelman, A C, Vyth-Dreese, F A, Melief, C J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anemia - chemically induced Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - immunology Dose-Response Relationship, Drug Drug Administration Schedule Drug Evaluation Feasibility Studies Female Humans Infusion Pumps Infusions, Intravenous Interleukin-2 - adverse effects Interleukin-2 - therapeutic use Kidney Neoplasms - blood Kidney Neoplasms - drug therapy Kidney Neoplasms - immunology Lymphocytes - drug effects Male Melanoma - blood Melanoma - drug therapy Melanoma - immunology Middle Aged Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!